BIMINI Biotech has received a MIT feasibility grant (€20.000) for the AUTO-WASP project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer
Leiden, 29 June 2023 – BIMINI Biotech, an innovative Leiden-based therapeutics start-up that develops novel therapeutics for hematological cancers, raised an additional investment of €250,000 from lead investor Libertatis Ergo Holding B.V. (LEH). The investment will be used in combination with a recently awarded Eurostars grant to progress the preclinical development of our lead candidates…
Lees meer
Leiden, 1 April 2023 – BIMINI Biotech, an innovative therapeutics startup, was recently awarded a Eureka Eurostars project with the aim of developing novel therapeutics for lymphomas. This project named HEMATO-WASP, brings together a unique consortium consisting of BIMINI Biotech (Leiden, the Netherlands), InnoSer Nederland (Leiden, the Netherlands) and the Institute of Oncology Research (IOR;…
Lees meer
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the MCL-TX project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer
Leiden, 15 October 2021 – BIMINI Biotech, an innovative therapeutics start-up that develops new cancer drugs, raised an investment of €250,000. The seed funding is provided by Libertatis Ergo Holding B.V. (LEH), a wholly owned subsidiary of Leiden University which supports and invests in spinout companies associated with Leiden University’s activities. BIMINI Biotech will leverage…
Lees meer
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the ONCO-ID project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer
Leiden, 26 November 2020 – BIMINI Biotech, an innovative therapeutics startup that develops new cancer drugs, has secured an investment of €200,000 from proof-of-concept fund UNIIQ to further develop its technology. The company aims to use the growth hormone receptor to uniquely inhibit cancer cell growth. The investment was announced digitally by Ida Haisma, director…
Lees meer
BIMINI Biotech is one of the 10 winners of the Academic Startup Competition 2020 and is now entitled to use the title ‘Best Academic Startup of 2020’ for the coming year. The other winning startups are DeNoize, Digi Bio, IamFluidics, Kaminari Medical, Lusoco, NC Biomatrix, Taylor, uCrowds and VanBoven. BIMINI Biotech develops innovative therapeutics in…
Lees meer
BIMINI Biotech has been awarded the Eureka INNOWIDE grant of €60.000 to set up a collaborative (pre-) clinical network of expert parties in India and accelerate cost-effective drug development. Together with our expert partner TheraIndx, we will make these initial steps for our lead compound. As such, BIMINI aims to create a global impact. The…
Lees meer
BIMINI Biotech has been awarded the NWO Take-off Phase 1 grant (€40.000) in collaboration with the Universitair Medisch Centrum Utrecht (UMCU) to perform an extensive feasibility study for BIMINI’s lead compound. The aim of the grant is to stimulate entrepreneurship and valorisation of breakthrough innovations that originate from Dutch Universities. This grant will help BIMINI…
Lees meer